Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Black Titan Corporation (BTTC : NSDQ)

• Company Description    Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $3.26 Daily Weekly Monthly 20 Day Moving Average: 98,774 shares Shares Outstanding: 1.33 (millions) Market Capitalization: $4.34 (millions) Beta: 1.34 52 Week High: $39.00 52 Week Low: $3.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -50.76% -52.04% 12 Week -33.87% -36.62% Year To Date 0.00% -12.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10 EAST 53RD STREET SUITE 3001 - NEW YORK,NY 10022 USA ph: 650-244-4990 fax: 650-244-4956 investors@titanpharm.com http://www.titanpharm.com

• General Corporate Information    Officers Chay Weei Jye - Chief Executive Officer Brynner Chiam - Director Avraham Ben-Tzvi, - Director Firdauz Edmin Bin Mokhtar - Director Francisco Osvaldo Flores Garcia - Director Peer Information Black Titan Corporation (CORR.) Black Titan Corporation (RSPI) Black Titan Corporation (CGXP) Black Titan Corporation (BGEN) Black Titan Corporation (GTBP) Black Titan Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G1156E102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 01/02/26 Share - Related Items Shares Outstanding: 1.33 Most Recent Split Date: 1.00 (0.05:1) Beta: 1.34 Market Capitalization: $4.34 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 01/02/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.56 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 71.62% vs. Previous Quarter: -4.84% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -108.60 03/31/25 - -145.92 ROA 09/30/25 - - 06/30/25 - -95.64 03/31/25 - -129.20 Current Ratio 09/30/25 - - 06/30/25 - 11.60 03/31/25 - 7.73 Quick Ratio 09/30/25 - - 06/30/25 - 11.60 03/31/25 - 7.73 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 2.10 03/31/25 - 2.05 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©